APA

Phillips G. L., Meisenberg B. R., Reece D. E., Adams V. R., Badros A. Z., Brunner J. L., Fenton R. G., Filicko J., Grosso D. L., Hale G. A., Howard D. S., Johnson V. P., Kniska A., Marshall K. W., Mookerjee B., Nath R., Rapoport A. P., Sarkodee-Adoo C., Takebe N., Vesole D. H., Wagner J. L. & Flomenberg N. (20041112). Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. : Bone marrow transplantation.

Chicago

Phillips G L, Meisenberg B R, Reece D E, Adams V R, Badros A Z, Brunner J L, Fenton R G, Filicko J, Grosso D L, Hale G A, Howard D S, Johnson V P, Kniska A, Marshall K W, Mookerjee B, Nath R, Rapoport A P, Sarkodee-Adoo C, Takebe N, Vesole D H, Wagner J L and Flomenberg N. 20041112. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. : Bone marrow transplantation.

Harvard

Phillips G. L., Meisenberg B. R., Reece D. E., Adams V. R., Badros A. Z., Brunner J. L., Fenton R. G., Filicko J., Grosso D. L., Hale G. A., Howard D. S., Johnson V. P., Kniska A., Marshall K. W., Mookerjee B., Nath R., Rapoport A. P., Sarkodee-Adoo C., Takebe N., Vesole D. H., Wagner J. L. and Flomenberg N. (20041112). Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. : Bone marrow transplantation.

MLA

Phillips G L, Meisenberg B R, Reece D E, Adams V R, Badros A Z, Brunner J L, Fenton R G, Filicko J, Grosso D L, Hale G A, Howard D S, Johnson V P, Kniska A, Marshall K W, Mookerjee B, Nath R, Rapoport A P, Sarkodee-Adoo C, Takebe N, Vesole D H, Wagner J L and Flomenberg N. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. : Bone marrow transplantation. 20041112.